Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Anisodine Hydrobromide in Acute Ischemic Stroke
NCT07513233Phase 1Active, not recruiting
- Sponsor
- Capital Medical University
- Start
- Apr 2026
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of anisodine in ischemic stroke (4 arms), sponsored by Capital Medical University. Primary endpoint: Incidence of Predefined Safety Events at 8 days. Started Apr 2026; status: active, not recruiting.
02
Drugs
anisodine
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07513233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07513233.